Ovid Therapeutics (NASDAQ:OVID) Bolsa

OVID THERAPEUTICS INC

Ovid Therapeutics

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Ovid Therapeutics Inc

Aquestive Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that Health Canada has granted the Company a meeting to discuss Aquestive's planned New Drug Submission (NDS) for Anaphylm&#x2122; (epinephrine) Sublingual Film in Canada. In addition, the Company has submitted an initial briefing book to the European Medicines Agency (EMA). The Company plans to submit a Marketing Authorization Application (MAA) to the EMA as soon as possible.
"These regulatory activities mark the pivotal first steps in Aquestive's comprehensive ex-U.S. regulatory strategy," said Dan Barber, President and Chief Executive Officer of Aquestive. "With our U.S. FDA New Drug Application recently accepted and a PDUFA target action date of January 31, 2026 established, we're now positioned to pursue parallel regulatory pathways with the potential to bring needle-free, device-free Anaphylm to patients underserved by current treatment options. Our proven ability to successfully bring innovative therapies to market globally, combined with our oral epinephrine approach, positions us to fundamentally change how patients and caregivers manage severe allergic reactions, including anaphylaxis."
Aquestive brings significant regulatory and commercialization experience to this expansion effort, with six FDA-approved drugs in its portfolio and products currently available across six continents. This established global footprint and regulatory track record positions the Company to efficiently navigate international approval processes.
Unlike traditional epinephrine auto-injectors that require needles, Anaphylm&#x2122; is administered orally, addressing critical barriers to treatment, including needle phobia, device malfunction concerns, and portability challenges that affect patient compliance and emergency response.
The Company's ex-U.S. regulatory strategy prioritizes markets with significant unmet medical needs and regulatory frameworks conducive to innovative therapies. EMA and Canada represent ideal initial international markets given their collaborative regulatory environment and substantial population of patients requiring reliable anaphylaxis treatment options.
Aquestive will continue to provide updates on its global regulatory approval progress as it works to establish Anaphylm as the new standard of care for the treatment of severe allergic reactions and anaphylaxis worldwide.

News

AQST

Aquestive Seeks Approval for Needle-Free Allergy Film in Canada and Europe, Eyes Global Expansion

Health Care

Contracts

General

TECH

Bio-Techne Partners To Distribute Spear Bio's Ultrasensitive Immunoassays, Enabling The Detection Of Low-abundance Biomarkers In Neurology, This Partnership Follows Bio-Techne's Participation In Spear Bio's $45M Series A Funding Round In 2024

JP Morgan analyst Adrian Huerta initiates coverage on Amrize (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRZ#NYSE">AMRZ</a>) with a Overweight rating and announces Price Target of $57.

Price Target

Initiation

Analyst Ratings

AMRZ

JP Morgan Initiates Coverage On Amrize with Overweight Rating, Announces Price Target of $57

GXO Signs Multi-Year Logistics Deal With Sky Italia To Manage Supply Chain, Storage, And Value-Added Services At Colleferro Site

Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) ("Acuren") today announced the expiration of the 60-day "go-shop" period ("Go-Shop Period") in connection with the previously announced Agreement and Plan of Merger with NV5 Global, Inc. (("NV5", NASDAQ:<a href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>), dated as of May 14, 2025 (the "Merger Agreement").
During the Go-Shop Period, NV5 was permitted to solicit and enter into negotiations with third parties that made a proposal or offer to acquire NV5. The Go-Shop Period expired at 11:59 p.m. ET on July 14, 2025. NV5 did not receive an NV5 Superior Proposal (as such term is defined in the Merger Agreement) during the Go-Shop Period.
The transactions contemplated by the Merger Agreement (the "Transactions") are expected to close in August of 2025, subject to customary closing conditions, including approval of each of Acuren and NV5's stockholders and receipt of regulatory approvals.

NVEE

Acuren Announces Expiration Of 60-Day "Go-Shop" Period In Connection With Agreement And Plan Of Merger With NV5 Global

SXTP

60 Degrees Pharmaceutical Determines Maximum Size Of Commercial Market For ARAKODA In Human Babesiosis To Be 380,000 Patients And $245M In Sales Annually

RFIL

RF Industries Secures $2.3M Follow-On Orders From Leading Aerospace Firm For Mission-Critical Custom Cabling Solutions

<ul>
<li>Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technology</li>
<li>Preclinical candidate data expected in early 2026, with exclusive option for Acumen to develop up to two development candidates for the treatment of Alzheimer's disease</li>
<li>Agreement follows more than one year of engagement to assess technical feasibility and profile series of development candidates &nbsp;</li>
</ul>

Biotech

ABOS

Acumen Pharmaceuticals Agrees With JCR Pharmaceuticals To Develop An Oligomer-targeted Enhanced Brain Delivery Therapy For Alzheimer's, JCR Will Receive An Upfront Payment And Will Be Eligible For An Additional Option Payment Should Acumen Exercise Its Exclusive Option To Develop Up To Two Development Candidates

Momentum builds behind global expansion strategy as brand aims to accelerate global net unit growth to achieve 2,000 international restaurants by 2028
DUBLIN, Ohio, July 15, 2025 /PRNewswire/ --&nbsp;The Wendy's Company announced today the finalization of two new franchise agreements that will add up to 190 new Wendy's&#xAE; restaurants across Italy and Armenia, marking a significant step forward in advancing the brand's strategic priority to accelerate global net unit growth. These commitments support Wendy's goal to achieve 70 percent of its unit growth outside the United States, with the Company expecting to reach 2,000 international restaurants by 2028.

Wendy's Company Finalizes Two New Franchise Agreements That Will Add Up To 190 New Wendy's Restaurants Across Italy And Armenia

Valvoline Releases FY24 Impact Report, Highlights Green Energy Push, Record Donations, And 2,000th Store Milestone

The agreement with Sky Italia, part of one of the leading entertainment groups in Europe, includes supply chain management and strategic value-added activities
MILAN, Italy, July 15, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=VQl4LAqgGyd9DAs3ChJKVgCOG3jJVMXJf83TR8fSjn1e9TnAkisxlkiSDIdZWeKygrZ5BuDOmxuspQHtjz4Cfg==">GXO Logistics, Inc.&nbsp;</a>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), the world's largest pure-play contract logistics provider, announced today that it has signed a multi-year agreement with Sky Italia, Italy's leading media &amp; entertainment company and a European entertainment leader. The agreement involves managing Sky's supply chain from the GXO warehouse in Colleferro where Sky's Business Core products (decoders and routers) and the Glass line (Smart TV) will be stored, as well as all the merchandising related to the Sky brand and TV series.

GXO Logistics Signs Multi-Year Agreement With Sky Italia For Supply Chain Management And Strategic Value-Added Activities In Italy

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is down nearly 5% from its all-time high of $122,838, trading at $116,880 as of Tuesday morning European time, as the <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46388685/bitcoin-shatters-all-time-high-to-hit-123000-as-ethereum-cracks-3000-and-xrp-taps-3">broader crypto market pauses</a> ahead of key macroeconomic data and reacts to a spike in large-scale on-chain activity. 
Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) has also dipped, down 2.5% to around $2,980.
What Experts Are Saying: Speaking with Benzinga, analysts say the move is largely a correction following a rapid run-up, compounded by heightened uncertainty around U.S. inflation data and growing signs of profit-taking by major holders.
"It's expected that after a large run, some correction is likely, especially following an uninterrupted move from $108K to $122K," said Nicolai Sondergaard, Research Analyst at Nansen. "We now see quite some heavy liquidation levels around $116.3K which is something to watch next as an immediate psychological level."
On-chain <a href="https://cryptoquant.com/insights/quicktake/68750927d04021572872b1f1-As-Retail-Chases-New-Highs-Whales-Are-Preparing-to-Sell-on-Binance?utm_source=telegram&amp;utm_medium=sns&amp;utm_campaign=quicktake&amp;utm_content=crazzyblockk">data</a> from CryptoQuant confirms that whales—large Bitcoin holders—have begun repositioning.
According to the firm, over 1,800 BTC were deposited onto Binance in a single day, with transactions over $1 million accounting for more than 35% of total inflows. 
These movements are typically viewed as precursors to increased volatility.
"This activity on Binance is a critical market signal," the firm noted, citing the exchange's dominant position in global spot and derivatives trading. 
The whale inflows suggest either profit-taking after the rally or preparations to hedge against downside risk ahead of CPI data.
Bitfinex analysts attributed the pullback to a combination of factors, including the recent rally's exhaustion and caution ahead of U.S. inflation figures due later today. "Bitcoin's recent pullback appears to be a natural breather following fresh all-time highs, alongside a cautious wait-and-see stance ahead of today's CPI release."
They added that if core inflation exceeds 3.2%, it could delay Federal Reserve easing, lift the dollar, and put pressure on risk assets like Bitcoin. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46394828/bitcoin-eth-xrp-solana-are-in-for-a-long-and-exhausting-bull-market-bernstein-predicts">Bitcoin, ETH, XRP, Solana Are In For A &#8216;Long And Exhausting Bull Market,&#8217; Bernstein Predicts</a>
"That would strengthen the dollar and hurt demand for non-yielding assets like Bitcoin, potentially extending the pullback by another 5–10%, based on prior CPI events."
On the other hand, a softer-than-expected print—such as a headline figure below 2.5% and core easing toward 2.9%—could revive bullish momentum. 
"A similar outcome today could push Bitcoin back toward $120K+ again especially if ETF inflows remain strong as they have in the past 2 weeks," Bitfinex said.
Longer term, structural factors such as U.S. tariffs could keep CPI elevated near 2.9%, which analysts say may limit the scale or duration of any policy-driven rally.
Altcoin markets, which had shown renewed strength following Bitcoin's recent high, are also under pressure. 
Ryan Lee, Chief Analyst at Bitget Research, pointed to a typical capital rotation pattern: "The recent surge in altcoins following Bitcoin's all-time high reflects a classic capital rotation pattern, as traders seek higher beta plays after BTC's initial breakout."
Lee said Ethereum could range between $2,500 and $3,500 in Q3 depending on DeFi activity and ETF momentum, while Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and XRP's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) trajectories will depend on network growth and regulatory outcomes respectively.
What&#8217;s Next: Market experts suggest that the next move for Bitcoin and by extension, the rest of the crypto market, will hinge on today's inflation data and how it influences interest rate expectations.
Whale behavior and ETF flows will also remain key variables.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46392541/how-donald-trumps-big-beautiful-bill-was-a-big-beautiful-boost-for-bitcoin">How Donald Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Was A &#8216;Big Beautiful Boost&#8217; For Bitcoin</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

$XRP

Bitcoin Dips Below $117,000: What On-Chain Data Reveals About The Next Big Price Shift

TD Cowen analyst Lance Vitanza maintains Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) with a Buy and raises the price target from $590 to $680.

MSTR

TD Cowen Maintains Buy on Strategy, Raises Price Target to $680

Piper Sandler analyst Derek Podhaizer initiates coverage on Select Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTTR#NYSE">WTTR</a>) with a Overweight rating and announces Price Target of $15.

WTTR

Piper Sandler Initiates Coverage On Select Water Solutions with Overweight Rating, Announces Price Target of $15

Earnings

Wells Fargo Q2 Net Interest Income Decreased 2% YoY; Consumer, Small And Business Banking Rose 3%

CORRECTION: JPMorgan Chase Q2 AUM $4.3 Trillion +18% YoY, Client Assets $6.4 Trillion +19% YoY, Average Loans +5%, Average Deposits +6%

Student‑loan expert Elaine Rubin warns the 7.7 million borrowers still enrolled in former President Joe Biden's stalled Saving on a Valuable Education plan have "a short window" to act before interest starts piling on their accounts again on August 1.
What Happened: The Education Department announced on July  9 that the interest‑free forbearance shielding SAVE borrowers <a href="https://www.benzinga.com/news/education/25/07/46336587/trump-administration-ends-interest-freeze-linda-mcmohan-says-biden-used-student-loan-forgiveness-to-win-votes">will expire</a> because the courts and the Trump administration say the plan exceeds federal authority.
Officials called the zero‑percent pause an illegal Biden giveaway and told borrowers to pick a new repayment option immediately.
"There is a short window before interest begins to accrue again … borrowers need to decide their next steps," <a href="https://www.cnbc.com/2025/07/14/trump-student-loan-save-forbearance.html">said</a> Rubin to CNBC, director of corporate communications at Edvisors, which counsels families on college costs.
Biden unveiled SAVE in 2023, touting it as the "most affordable plan ever," but Republican‑led states sued, and an appeals court <a href="https://www.benzinga.com/government/24/07/39849095/appeals-court-blocks-bidens-save-student-loan-debt-relief-plan">blocked its key features</a> last year. The administration responded by freezing payments and interest and that relief ends in less than three weeks.
See Also: <a href="https://www.benzinga.com/markets/tech/25/07/46410520/elon-musks-tesla-once-built-cars-in-a-tent-to-meet-production-goals-now-mark-zuckerberg-is-channeling-his-nemesis-as-meta-builds-ai-data-centers-in-tents">Elon Musk&#8217;s Tesla Once Built Cars In A Tent To Meet Production Goals: Now, Mark Zuckerberg Is Channeling His Nemesis As Meta Builds AI Data Centers In Tents</a>
Why It Matters: Education Secretary Linda McMahon said resuming interest restores "fiscal responsibility" and urged borrowers to switch to the long‑standing Income‑Based Repayment plan until a new Repayment Assistance Plan (RAP) debuts in 2026. <a href="https://www.benzinga.com/news/25/05/45601752/trumps-big-beautiful-bill-passes-house-taxes-student-loans-medicaid-and-what-else-is-changing-for-am">RAP is part</a> of Trump's sweeping "One Big Beautiful Bill," which also caps graduate borrowing and scraps most other income‑driven programs.
Analysts say the about‑face could raise monthly bills by $100 to $200 for many SAVE users and swell balances by an average $3,500 a year. Servicers already face a 2 million‑application <a href="https://protectborrowers.org/new-court-filing-reveals-backlog-of-2-million-borrower-payment-plan-applications/">backlog</a>, meaning some borrowers may not land in a new plan before charges restart.
Rubin urges borrowers to log in to StudentAid.gov's loan simulator, compare costs under IBR, and set up auto‑pay to avoid missed‑payment fees once interest resumes. "Waiting until July 31 is too late," she said.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46410556/trump-admin-pours-1-billion-into-cyber-warfare-capabilities-while-slashing-us-cybersecurity-defenses">Trump Admin Pours $1 Billion Into Cyber Warfare Capabilities — While Slashing US Cybersecurity Defenses</a></li>
</ul>
Image Via Shutterstock

Education

Biden's SAVE Plan Crumbles As Trump Team Ends Relief: 'Short Window' Before Interest Hits 7.7 Million Borrowers, Expert Warns

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fspire.com%2F&amp;esheet=54290179&amp;newsitemid=20250715303922&amp;lan=en-US&amp;anchor=Spire+Global%2C+Inc.&amp;index=1&amp;md5=c232624093783619e59ade13a6f4359b">Spire Global, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) ("Spire" or "the Company"), a global provider of space-based data, analytics and space services, was awarded a $1.2 million, two-month task order extension modification from NASA to continue participation in its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fearthdata.nasa.gov%2Fesds%2Fcsdap&amp;esheet=54290179&amp;newsitemid=20250715303922&amp;lan=en-US&amp;anchor=Commercial+Satellite+Data+Acquisition+%28CSDA%29+Program&amp;index=2&amp;md5=9753772b88fefcb17d536480ef1f450c">Commercial Satellite Data Acquisition (CSDA) Program</a>. The award is an extension to a $6.7 million, 12-month task order awarded in August 2024.
Under the task order, Spire will continue to deliver its comprehensive Earth observation data, including GNSS radio occultation, GNSS Reflectometry, and space weather measurements. As one of the original vendors for the CSDA Program, Spire has provided Earth observation data to NASA's CSDA Program since 2018.
Spire's data will support U.S. government-funded research with the objective of enhancing global weather forecasting, atmospheric profiling, and climate research.

SPIR

Spire Global Bags $1.2M, Two-Month Task Order Extension Modification From NASA To Continue Participation In Commercial Satellite Data Acquisition Program

Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.40 by 13.96 percent. This is a 20.3 percent increase over earnings of $1.33 per share from the same period last year. The company reported quarterly sales of $20.822 billion which beat the analyst consensus estimate of $20.781 billion by 0.20 percent. This is a 0.64 percent increase over sales of $20.689 billion the same period last year.

Earnings Beats

Wells Fargo Q2 EPS $1.60 Beats $1.40 Estimate, Sales $20.822B Beat $20.781B Estimate

Needham analyst Charles Shi maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and raises the price target from $650 to $660.

SNPS

Needham Maintains Buy on Synopsys, Raises Price Target to $660

Press Releases

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Management

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Comments

Ovid Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL